BNB Plus Corp.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBNB Plus Corp. is a digital asset treasury company that holds BNB cryptocurrency as its primary reserve asset and also operates a nucleic acid production subsidiary, LineaRx.
What they do
The company launched a BNB-focused digital asset treasury strategy in October 2025, using proceeds from financings to accumulate BNB and generate yield through staking, restaking, liquidity provision, and other DeFi opportunities. It also holds units of the OBNB Osprey BNB Chain Trust. Separately, through its LineaRx subsidiary, it commercializes proprietary nucleic acid production solutions for biopharmaceutical and diagnostic markets.
Revenue drivers
- BNB digital asset treasury — Plans to generate yield from staking, restaking, liquid staking, Binance Launch Pool airdrops, liquidity provision, and collateralized lending; still in the accumulation and framework-building phase.
- OBNB Trust Units — Holds units of the OBNB Osprey BNB Chain Trust; intends to sell units for cash to buy BNB or redeem underlying BNB assets.
- LineaRx nucleic acid production — Commercializes cell-free DNA and RNA production for advanced biotherapeutics and diagnostics; historically a source of revenue but the filing does not specify its current size.
Recent performance
Annual revenue was $2.1M in both fiscal years 2024 and 2025, down from $13.4M in 2023. Net loss widened to $15.2M in 2025 from $7.0M in 2024, and operating cash flow was -$12.2M in 2025. Quarterly revenue fluctuated from $199,429 (Sept 2025) to $1.0M (March 2026) and $605,306 (June 2026). The latest balance sheet shows total assets of $15.0M, liabilities of $2.0M, and shareholder equity of $9.5M.
Strategy
Primary focus is the BNB Strategy, which includes accumulating BNB tokens and building the framework for yield generation via Binance-native and DeFi opportunities. The company plans to use proceeds from financings and potential operating cash flow to increase BNB reserves. It also aims to monetize or redeem its OBNB Trust Units to further the BNB Strategy. Management expects LineaRx to narrow losses significantly in Q1 FY26 and approach profitability.
Risks
- Unproven BNB yield strategy — The BNB Strategy is newly launched and has not demonstrated ability to generate returns, with management acknowledging risks related to an unproven yield generation strategy.
- Cryptocurrency price volatility — The price of common stock may be highly correlated to the price of BNB and other digital assets, which are volatile and subject to regulatory and market uncertainties.
- Material weakness in internal controls — A material weakness in internal controls over financial reporting has been identified, which could lead to loss of investor confidence.
- Need for additional capital — If the company cannot raise sufficient capital on acceptable terms, it may not be able to expand BNB reserves or fund operations.
Outlook
Management projects that LineaRx will significantly narrow losses in FY26Q1 (ending December 31, 2025) and approach profitability. The company is in the process of accumulating BNB and building the framework to launch its yield-generating activities. It continues to explore the sale or redemption of OBNB Trust Units to support the BNB Strategy. Uncertainties remain regarding the actual returns from the BNB Strategy and the ability to raise additional funds.